SCM
TVTX icon

Silverarc Capital Management’s Travere Therapeutics TVTX Stock Holding History

Silverarc Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-408,849
Closed -$7.33M – 84
2025
Q1 		$7.33M Buy
408,849
+131,484
+47% +$2.67M 1.5% 20
2024
Q4 		$4.83M Buy
+277,365
New +$4.91M 1.06% 33
2021
Q2 		– Sell
-20,000
Closed -$499K – 113
2021
Q1 		$499K Buy
+20,000
New +$553K 0.27% 71

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverarc Capital Management's TVTX Position: Q2 2025 in Review

Silverarc Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 408,849 shares — an estimated $7.33M sold.

Silverarc Capital Management first reported a position in TVTX in Q1 2021 and held it in 3 quarters. The position peaked at $7.33M in Q1 2025. 212 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Silverarc Capital Management reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 408,849 Travere Therapeutics shares in Q2 2025, an estimated $7.33M.
  • Silverarc Capital Management first reported a position in Travere Therapeutics in Q1 2021 and held it in 3 quarters.
  • Silverarc Capital Management's Travere Therapeutics position peaked at $7.33M in Q1 2025.
  • 212 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.